Format

Send to

Choose Destination
Nat Rev Clin Oncol. 2011 Feb;8(2):85-96. doi: 10.1038/nrclinonc.2010.189. Epub 2010 Dec 14.

Beyond chemotherapy: new agents for targeted treatment of lymphoma.

Author information

1
Department of Lymphoma and Myeloma, Unit 429, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. ayounes@mdanderson.org

Erratum in

  • Nat Rev Clin Oncol. 2011 Mar;8(3):124.

Abstract

An improved understanding of the molecular biology of cancer cell growth and survival and the role of the microenvironment in supporting the survival of cancer cells, including lymphoma cells, has led to the identification of a number of potential therapeutic targets. Despite these advances, drug development for lymphoma remains slow, inefficient, and frequently unfocused. Future work should focus on identifying 'driver' molecular defects of oncogenic pathways that can be targeted therapeutically, discovering predictive biomarkers for treatment response, and prioritizing promising drugs to accelerate their approval. This Review summarizes the current development status of novel agents for lymphoma and discusses strategies to move the field forward.

PMID:
21151205
PMCID:
PMC3192435
DOI:
10.1038/nrclinonc.2010.189
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center